BPI Labs distributes unapproved Epinephrine Chloride Nasal Solution in a vial FDA says can be mistaken for injectable epinephrine.
What happened
FDA reviewed BPI Labs' Epinephrine Chloride Nasal Solution 1 mg/mL, 10 mL, including its labeling. FDA found the product is an unapproved new drug (a drug without an FDA-approved application) and is misbranded (packaged in a misleading way) because its glass vial appears identical to BPI's FDA-approved epinephrine injection vial; FDA has received reports of confusion that led to erroneous preparation of the nasal product for injection. FDA also cited a January 16, 2025 news release warning health care professionals not to use epinephrine nasal solutions from BPI Labs and Endo USA.
What FDA found
BPI markets Epinephrine Chloride Nasal Solution without an FDA-approved drug application.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a), 331(d)FDA says no adequate and well-controlled trials in published literature show the nasal solution is generally recognized as safe and effective for its labeled uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)The nasal solution's glass vial looks the same as the vial for BPI's approved epinephrine injection, which can mislead users into thinking the nasal product is for injection.
FD&C Act section 502(i)(1), 21 U.S.C. 352(i)(1)FDA received reports that confusion between the nasal solution and the approved injection led to erroneous preparation of the nasal product for injection.
BPI introduces a misbranded drug into interstate commerce.
FD&C Act section 301(a), 21 U.S.C. 331(a)
What FDA wants
FDA asks BPI to notify it in writing within fifteen working days of the specific steps taken to address the violations, including an explanation and supporting documents. BPI should also report progress updating its drug listing eDRLS files, or state if it no longer makes or markets the product.
Who should pay attention
- healthcare professionals who store or administer epinephrine products
- hospitals and pharmacies that stock epinephrine nasal solutions
- companies that package topical drugs in injection-style vials
This is a summary. Read the original letter on fda.gov.